Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma | MicrobiomeTrials← Back to trialsNCT07708961
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08-28Est. Completion: 2036-08-31
Enrollment target: 60 participants Locations- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Other microbiome trials you might be interested in
GlioblastomaGliosarcomaGBMGlioblastoma MultiformeGlioblastoma, IDH-wildtypeRecurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has bee…
Chicago, United StatesEst. completion Dec 31, 2027
Astrocytoma, IDH-Mutant, Grade 4Diffuse GliomaGlioblastoma, IDH-Wildtype
Secondary Glioblastoma
This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with gliom…
Anchorage, United StatesEst. completion Jun 30, 2027